“In Dr. Christian Fischer, we have gained an outstanding leader as CEO. He brings with him 24 years of industry experience and has demonstrated his entrepreneurial drive in various roles at BASF, both in Germany and abroad. Over the past few years, Gerresheimer has refined its strategic focus, made successful acquisitions and divestments, and established numerous operational initiatives – these will ensure a smooth and seamless transition,” explained Dr. Axel Herberg, Chairman of the Supervisory Board of Gerresheimer AG.
“Gerresheimer AG is a highly successful, international company and a trusted partner to the pharma and healthcare industry. I am looking forward to my new role in this exciting company and market,” added Dr. Christian Fischer.
Uwe Röhrhoff will leave the Company on August 31, 2017. Following Dr. Christian Fischer’s induction in August 2017, Uwe Röhrhoff will continue to support his successor in an advisory capacity for a further three months.
Dr. Christian Fischer
Dr. Christian FischerDr. Christian Fischer was born in Furth im Wald, Germany, in 1964. From 1984 to 1988 he studied chemistry at the University of Regensburg, where he gained his doctorate in 1991. He then studied business administration in Mannheim from 1993 to 1996. In 2014, he was appointed an honorary professor at the Technical University of Munich (TUM).
Dr. Fischer has worked at BASF since 1993. Having started his career as a laboratory team leader, he has held various positions at the company, including Deputy Division Manager, Global Marketing Director, Sales Director and Group Vice President in different divisions in Ludwigshafen and Hong Kong. He was President, Advanced Materials & Systems Research and currently serves as President, Performance Chemicals, at BASF SE in Ludwigshafen. Dr. Christian Fischer is married and has one daughter.
Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With plants in Europe, North America, South America and Asia, Gerresheimer generates revenues of around EUR 1.4bn. The company’s comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.